Amanote Research
Register
Sign In
Correction: Durable Therapeutic Efficacy Utilizing Combinatorial Blockade Against IDO, CTLA-4, and PD-L1 in Mice With Brain Tumors
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-14-3211
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
February 1, 2015
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Dual Blockade of PD-1 and CTLA-4 Combined With Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors—Response
Cancer Research
Cancer Research
Oncology
Rational Combination of Oncolytic Vaccinia Virus and PD-L1 Blockade Works Synergistically to Enhance Therapeutic Efficacy
Nature Communications
Astronomy
Genetics
Molecular Biology
Biochemistry
Chemistry
Physics
Tumor Vaccines Expressing Flt3 Ligand Synergize With CTLA-4 Blockade to Reject Preimplanted Tumors
Cancer Research
Cancer Research
Oncology
Oncolytic Virus and PD-1/PD-L1 Blockade Combination Therapy
Oncolytic Virotherapy
Therapeutic Blockade of PD-L1 and LAG-3 Rapidly Clears Established Blood-Stage Plasmodium Infection
Nature Immunology
Allergy
Immunology
CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice
Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer Research
Allergy
Immunology
Pharmacology
PD-L1 Expression in Inflammatory Myofibroblastic Tumors
Modern Pathology
Forensic Medicine
Pathology
7. PD-L1 in Triple Negative Breast Cancer – Optimal Testing for Therapeutic Efficacy
Pathology
Forensic Medicine
Pathology
CTLA-4 Blockade Synergizes With Cryoablation to Mediate Tumor Rejection
OncoImmunology
Oncology
Allergy
Immunology